A Light Activated Glucagon Trimer with Resistance to Fibrillation
Source abstract
Abstract
In this work, we have brought the release of glucagon under the control of light. The aim of this approach is to allow minimally invasive, two-hormone control of blood glucose. Glucagon has two major challenges associated with its therapeutic application: (1) the required amount and timing of glucagon release is highly variable, and (2) glucagon rapidly fibrillates in solution, forming aggregates that are inactive. We have developed a light activated glucagon trimer, in which we have joined three glucagon molecules via light cleaved linkers. We demonstrated that this material can be stimulated by light to release glucagon in a predictable manner. In addition, we demonstrated that in the absence of light, the trimer does not form fibrils and thus releases normal unfibrillated glucagon upon irradiation. These qualities make this material ideal for incorporation into a two hormone light-activated artificial pancreas system.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Attention Deficit Hyperactivity Disorder
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri 64108, United States
Funding
School of Pharmacy, University of Missouri-Kansas City · National Institute of Diabetes and Digestive and Kidney Diseases · University of Missouri
References (40)
Show source-provided references
1. 10.1002/ange.20120726410.1002/ange.201207264 ↗
2. 10.1021/jacs.7b0846510.1021/jacs.7b08465 ↗
3. 10.1016/bs.mie.2019.04.00810.1016/bs.mie.2019.04.008 ↗
4. 10.1021/acs.molpharmaceut.9b0014010.1021/acs.molpharmaceut.9b00140 ↗
5. 10.1002/mabi.20150047110.1002/mabi.201500471 ↗
6. 10.1021/acs.molpharmaceut.9b0080610.1021/acs.molpharmaceut.9b00806 ↗
7. 10.1021/acs.molpharmaceut.6b0063310.1021/acs.molpharmaceut.6b00633 ↗
8. 10.1038/nrendo.2011.3210.1038/nrendo.2011.32 ↗
9. 10.1136/bmj.d185510.1136/bmj.d1855 ↗
10. 10.2337/dc07-196710.2337/dc07-1967 ↗
11. 10.1089/dia.2018.008810.1089/dia.2018.0088 ↗
12. 10.1016/j.jpeds.2007.10.00610.1016/j.jpeds.2007.10.006 ↗
13. 10.1111/jdi.1235710.1111/jdi.12357 ↗
14. 10.1177/19322968120060042910.1177/193229681200600429 ↗
15. 10.1089/dia.2010.006810.1089/dia.2010.0068 ↗
16. Shah V. N. · 2014
17. 10.1089/dia.2009.016110.1089/dia.2009.0161 ↗
18. 10.1152/ajpendo.00492.200210.1152/ajpendo.00492.2002 ↗
19. 10.2337/cd18-002810.2337/cd18-0028 ↗
20. 10.1016/j.peptides.2015.03.01110.1016/j.peptides.2015.03.011 ↗
21. 10.1126/scitranslmed.300061910.1126/scitranslmed.3000619 ↗
22. 10.1016/j.jprocont.2018.05.00310.1016/j.jprocont.2018.05.003 ↗
23. 10.1007/s00125-016-4107-010.1007/s00125-016-4107-0 ↗
24. 10.1111/dom.1270710.1111/dom.12707 ↗
25. 10.1503/cmaj.12126510.1503/cmaj.121265 ↗
26. 10.1111/dom.1266310.1111/dom.12663 ↗
27. 10.1016/j.peptides.2013.04.00510.1016/j.peptides.2013.04.005 ↗
28. 10.1111/j.1432-1033.1969.tb00735.x10.1111/j.1432-1033.1969.tb00735.x ↗
29. 10.1177/193229681456513110.1177/1932296814565131 ↗
30. 10.1016/0300-483X(75)90081-510.1016/0300-483X(75)90081-5 ↗
31. 10.1096/fj.13-23544010.1096/fj.13-235440 ↗
32. 10.1021/jo961602x10.1021/jo961602x ↗
33. 10.1039/C3PY01376F10.1039/C3PY01376F ↗
34. 10.1021/ar200059z10.1021/ar200059z ↗
35. 10.1089/dia.2017.020410.1089/dia.2017.0204 ↗
36. 10.1023/B:PHAM.0000033016.36825.2c10.1023/B:PHAM.0000033016.36825.2c ↗
37. 10.1016/j.ymeth.2004.03.01210.1016/j.ymeth.2004.03.012 ↗
38. 10.1016/j.bpj.2015.01.00410.1016/j.bpj.2015.01.004 ↗
39. 10.1016/0005-2795(73)90302-410.1016/0005-2795(73)90302-4 ↗
40. 10.1021/bi00590a02610.1021/bi00590a026 ↗